Marlana M. Orloff, MD, is an associate professor at Jefferson University and physician in the Department of Medical Oncology at Sidney Kimmel Cancer Center.
In this segment, our panel puts the current treatment landscape for metastatic uveal melanoma into historical context, walking through the long series of agents that failed to move the needle before the recent shift in what is achievable for these patients.
In this segment, our panel goes deeper into the molecular workup for uveal melanoma, covering the prognostic significance of BAP1, SF3B1, and EIF1AX mutations alongside gene expression profiling, and explaining how PRAME is emerging as both a prognostic marker and a potential therapeutic target.
Marlana M. Orloff, MD, discusses efficacy and safety findings from the phase 2/3 OptimUM-02 trial in uveal melanoma.
In this segment, our panel walks through the initial workup for a patient newly diagnosed with uveal melanoma, with a focus on how gene expression profiling and PRAME status are used to stratify patients by metastatic risk.
In this segment, our panel establishes why uveal melanoma is a fundamentally different disease from cutaneous melanoma and why that distinction matters for every treatment decision that follows.
Marlana Orloff, MD, reviews primary OptimUM-02 data showing darovasertib plus crizotinib significantly improved progression-free survival and response rates versus investigator’s choice in first-line HLA-A2–negative metastatic uveal melanoma, with overall survival data not yet mature.
Marlana Orloff, MD, discusses efficacy findings with darovasertib plus crizotinib in metastatic uveal melanoma that were seen in the OptimUM-01 trial.
Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.
The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.
Drs Richard D. Carvajal and Marlana M. Orloff highlight variables that should be considered when assessing the appropriateness for treating patients with uveal melanoma with tebentafusp.
Advice to help educate patients about symptoms and management of cytokine release syndrome following treatment with tebentafusp for uveal melanoma.
What to know about treatment response and treatment-related adverse events with tebentafusp for uveal melanoma.
Potential sequencing strategies with novel therapies such as tebentafusp for uveal melanoma.
Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression.
Implications for treating uveal melanoma with tebentafusp based on responses demonstrated by the IMCgp100-102 and IMCgp100-202 clinical studies.
Drs Richard D. Carvajal and Marlana M. Orloff comment on tebentafusp’s mechanism of action (MOA) and explain what makes the therapy attractive for uveal melanoma.
A brief explanation regarding the difference between uveal melanoma and skin melanoma and an overview of standard treatment approaches used to treat patients with uveal melanoma.
July 23rd 2021
July 23rd 2021
